Full-Time

Director Chemical Development

Updated on 9/4/2026

Treeline Biosciences

Treeline Biosciences

51-200 employees

Biotech firm discovering cancer therapies.

Compensation Overview

$222.3k - $243.3k/yr

Watertown, MA, USA

In Person

Travel to domestic and international CDMO sites is expected approximately 20% of the time.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Medicinal Chemistry
Word/Pages/Docs
Quality Assurance (QA)
Data Analysis
Excel/Numbers/Sheets

Get referred to Treeline Biosciences

See people who can refer or advise you

Requirements
  • A Ph.D. in Organic Chemistry or a related discipline with at least 12 years of experience, or a Master's degree with at least 15 years of experience in chemical development of small-molecule pharmaceuticals.
  • Demonstrated successful leadership in a pharmaceutical CMC drug substance development role.
  • A track record of leading and managing small-molecule drug substance programs in a 100% outsourced environment.
  • Strong vendor and supplier management skills, communication skills, and cross-functional collaboration skills.
  • Broad experience working with and managing external contract development and manufacturing organization partners, including performance and quality metrics and master services agreement negotiation.
  • Expertise in small-molecule process development and oversight of good manufacturing practice manufacturing, including technology transfer and process validation.
  • Experience authoring and reviewing technical documents, including development reports, master batch records, analytical testing methods, and specifications.
  • Deep understanding of global regulatory requirements for the manufacture, testing, and control of drug substances.
  • Demonstrated success authoring drug substance sections of investigational new drug applications, investigational medicinal product dossiers, and marketing applications, and responding to regulatory agency review inquiries.
  • Strong project leadership skills and the ability to manage complex timelines, multiple stakeholders, and evolving program priorities.
  • An understanding of basic budgeting processes.
  • An understanding of industry trends, practices, techniques, standards, and their impact on program strategy and execution.
  • Ability to travel 20% to domestic and international contract development and manufacturing organization sites.
  • Fluency with Microsoft Word, Excel, PowerPoint, Project, and JMP or similar statistical tools.
Responsibilities
  • Lead and manage cross-functional teams engaged in external good manufacturing practice manufacturing of drug substance, drug substance intermediates, and starting materials.
  • Collaborate with medicinal chemistry partners to support candidate selection and developability assessments, and advise and assist with sourcing scaffolds and intermediates as appropriate.
  • Provide technical and functional project leadership for drug substance process development, manufacturing, and contract development and manufacturing organization partner management.
  • Oversee technical transfer activities between contract development and manufacturing organizations as needed to ensure supply continuity.
  • Collaborate with Analytical Development to ensure development and validation of analytical test methods for drug substances.
  • Ensure timely review and approval of batch records, specifications, change controls, and other documentation to ensure supply continuity.
  • Provide technical input to deviation investigations to assess impacts on products and manufacturing processes.
  • Partner with Quality Assurance and CMC Regulatory to develop and implement processes and controls ensuring drug substance batches meet specifications and adhere to good manufacturing practices when required.
  • Support investigations, root-cause identification, and corrective and preventive action implementation associated with manufacturing deviations and related quality events.
  • Work with Analytical Development and Quality Control, Quality Assurance, CMC Regulatory, Supply Chain, and external manufacturing operations to achieve timelines, budgets, and technical, regulatory, and business goals and milestones.
  • Author and review technical documents, process development reports, and drug substance sections for investigational new drug applications, investigational medicinal product dossiers, and global marketing applications.
  • Stay current with applicable global regulations and industry standards.
  • Represent Drug Substance and Chemical Development in meetings with the Food and Drug Administration, European Medicines Agency, and related regulatory authorities.
  • Supervise one or more process chemists, as needed.
Desired Qualifications
  • Experience developing and commercializing oncology drugs.

Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.

Company Size

51-200

Company Stage

Series A

Total Funding

$1.1B

Headquarters

Stamford, Connecticut

Founded

2021

Get referred to Treeline Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 8, 2026 merger adds $450 million net cash and $900 million runway.
  • TLN-121 showed complete responses in Phase 1 DLBCL, follicular lymphoma, and TFH PTCL.
  • Treeline expects TLN-121 combination dosing with Roche in Q4 2026.

What critics are saying

  • Standard BioTools merger faces stockholder litigation over fairness and process.
  • TLN-121 remains Phase 1; one safety miss or weak efficacy kills valuation.
  • If the merger closes late or fails, Treeline lacks public-market financing and revenue.

What makes Treeline Biosciences unique

  • Josh Bilenker's team raised $1.2 billion and keeps multiple oncology shots alive.
  • TLN-121, TLN-254, TLN-372, and TLN-499 span lymphoma, KRAS, and platform biology.
  • Roche's September 2, 2026 collaboration validates TLN-121 with Columvi and Lunsumio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

2%
Clinical Trials Arena
Sep 3rd, 2026
Treeline and Roche collaborate on TLN-121 combo trial for BCL.

Treeline and Roche collaborate on TLN-121 combo trial for BCL. Treeline intends to start combination dosing in these cohorts in the fourth quarter of 2026. Treeline Biosciences has signed a clinical trial collaboration and supply agreement with Roche for a Phase I study assessing the combination of Treeline's BCL6 degrader, TLN-121, with Roche's CD20xCD3 T-cell-engaging bispecific antibodies, glofitamab (Columvi) and mosunetuzumab (Lunsumio), in patients with B-cell lymphomas (BCL). The trial will assess the combinations in separate cohorts, including individuals with diffuse large B-cell lymphoma (DLBCL). Under the collaboration, Treeline Biosciences will sponsor and oversee the Phase I dose-escalation and expansion study, with Roche supplying glofitamab and mosunetuzumab for particular expansion cohorts. Treeline intends to start combination dosing in these cohorts in the fourth quarter of 2026. Treeline co-founder and CEO Josh Bilenker said: "CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. Clinical Trials Arena is excited to build on that progress in collaboration with Roche. "We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumour activity of both CD20xCD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T-cells and B-cells." TLN-121 has shown single-agent activity, including complete responses, in an ongoing Phase I trial in late-line DLBCL, follicular lymphoma and T follicular helper peripheral T-cell lymphoma. Treeline is a clinical-stage biopharmaceutical company with a pipeline in oncology, neurology and immunology. Last month, Evexta Bio and Roche entered a clinical trial collaboration and supply agreement for a Phase Ib study investigating the combination of rupitasertib and giredestrant in patients with advanced or metastatic breast cancer. This marks the first clinical collaboration for Evexta Bio involving its investigational compound rupitasertib and for Roche with giredestrant, its selective estrogen receptor degrader (SERD). Give your business an edge with its leading industry insights.

cash.ch
Sep 2nd, 2026
Roche cooperates with Treeline on lymphoma therapy.

Roche cooperates with Treeline on lymphoma therapy. Roche is collaborating with the US biotech company Treeline Biosciences on the development of a new combination therapy for certain forms of lymphoma. 02.09.2026 04:50 In the collaboration, Treeline's drug candidate TLN-121 in combination with Roche's drugs Columvi (glofitamab) and Lunsumio (mosunetuzumab) will be investigated. The combinations are to be studied in patients with B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), as Treeline announced on Wednesday. Treeline will finance and conduct the phase 1 study, while Roche will provide the already approved cancer drugs glofitamab and mosunetuzumab for certain study groups. Financial details were not disclosed. Treeline plans to begin the combined treatment in the fourth quarter of 2026. Preclinical investigations have provided evidence that TLN-121 could enhance the effect of the two Roche therapies. TLN-121 is currently already being tested as a monotherapy in a phase 1 study.

Contract Pharma
Sep 2nd, 2026
Treeline, Roche partner on TLN-121 lymphoma trial.

Treeline, Roche partner on TLN-121 lymphoma trial. Phase 1 study will evaluate TLN-121 with Roche's glofitamab and mosunetuzumab in patients with B-cell lymphomas. September 2, 2026 Associate Editor, Contract Pharma Treeline Biosciences Inc. has entered into a clinical trial collaboration and supply agreement with Roche to study TLN-121, Treeline's BCL6 degrader, alongside Roche's CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in patients with B-cell lymphomas. The Phase 1 study will evaluate the combinations in separate cohorts, including patients with diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of B-cell lymphoma. Treeline will sponsor and conduct the Phase 1 dose-escalation and expansion study, while Roche will provide glofitamab and mosunetuzumab for specified expansion cohorts. Treeline expects to begin combination dosing in those cohorts in the fourth quarter of 2026. "CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche," said Josh Bilenker, M.D., co-founder and CEO of Treeline. TLN-121 is already being evaluated as a single agent in an ongoing Phase 1 clinical trial, where Treeline said it has shown activity, including complete responses in late-line DLBCL, follicular lymphoma (FL), and T follicular helper peripheral T-cell lymphoma (TFH PTCL). The collaboration is intended to test whether degrading BCL6 can make lymphoma cells more responsive to T-cell-engaging therapies, a strategy supported by Treeline's preclinical findings. "We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumor activity of both CD20xCD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T- and B-cells," Bilenker added.

My Malone Telegram
Jun 19th, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN)...

BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN), Standard BioTools Inc. (Nasdaq - LAB). * Jun 19, 2026 BALA CYNWYD, Pa., June 19, 2026 (GLOBE NEWSWIRE) - Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you. AstroNova, Inc. (Nasdaq - ALOT) Under the terms of the Merger Agreement, AstroNova will be acquired by Arcline Investment Management for $29.00 per share in cash in an all-cash transaction with a total enterprise value of approximately $272 million. The investigation concerns whether the AstroNova Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Open Lending Corporation (Nasdaq - LPRO) Under the terms of the Merger Agreement, Open Lending will be acquired by ANV Group Holdings Ltd. for $3.15 per share. The investigation concerns whether the Open Lending Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Huntsman Corporation (NYSE - HUN) Under the terms of the Merger Agreement, Huntsman will be acquired by Olin Corporation (NYSE - OLN) whereby Huntsman shareholders will receive 0.5476 shares in Olin for every one (1) share of Huntsman. Upon completion of the transaction, Olin shareholders will own approximately 54.5% and Huntsman shareholders will own approximately 45.5% of the combined company. The investigation concerns whether the Huntsman Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Standard BioTools Inc. (Nasdaq - LAB) Under the terms of the Merger Agreement, Standard BioTools will be acquired by Treeline Biosciences, Inc. At the closing of the proposed combination, pre-merger Standard BioTools stockholders are expected to own approximately 16% of the combined company, and pre-merger Treeline stockholders are expected to own approximately 84% of the combined company. The investigation concerns whether the Standard BioTools Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Endpoints News
Jun 8th, 2026
Treeline to go public via reverse merger with Standard BioTools.

Treeline to go public via reverse merger with Standard BioTools. News reporter. Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.